Trade

with

Progenics Pharmaceuticals Inc
(NASDAQ: PGNX)
AdChoices
4.68
-0.17
-3.51%
After Hours :
-
-
-

Open

4.96

Previous Close

4.85

Volume (Avg)

755.08k (969.36k)

Day's Range

4.65-5.00

52Wk Range

3.10-7.45

Market Cap.

325.52M

Dividend Rate ( Yield )

-

Beta

1.53

Shares Outstanding

69.56M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 7.86M

    • Net Income

    • -42.57M

    • Market Cap.

    • 325.52M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -553.35

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.53

    • Forward P/E

    • -6.33

    • Price/Sales

    • 41.84

    • Price/Book Value

    • 3.31

    • Price/Cash flow

    • -8.15

      • EBITDA

      • -42.04M

      • Return on Capital %

      • -30.41

      • Return on Equity %

      • -41.62

      • Return on Assets %

      • -30.41

      • Book Value/Share

      • 1.41

      • Shares Outstanding

      • 69.56M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 11.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.74

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -18.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -34.98

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 91.33

            • 82.75

            • Pre-Tax Margin

            • -558.44

            • 39.38

            • Net Profit Margin

            • -553.35

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 96.90

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -344.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 20.39

              • 2.92

              • Quick Ratio

              • 19.95

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.35

              • 2.21

              • Book Value/Share

              • 1.41

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -7.57

                • 188.68

                • P/E Ratio 5-Year High

                • -18.34

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.28

                • 124.82

                • Price/Sales Ratio

                • 41.84

                • 8.72

                • Price/Book Value

                • 3.31

                • 7.95

                • Price/Cash Flow Ratio

                • -8.15

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -41.62

                    (-41.50)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -30.41

                    (-35.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -41.62

                    (-41.50)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.05

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -42.98M
                  Operating Margin
                  -546.68
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -8.15
                  Ownership

                  Institutional Ownership

                  75.14%

                  Top 10 Institutions

                  60.39%

                  Mutual Fund Ownership

                  39.78%

                  Float

                  80.32%

                  5% / Insider Ownership

                  2.30%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Kaufmann Fund

                  •  

                    9,211,000

                  • 0.00

                  • 13.24

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    4,065,966

                  • 0.00

                  • 5.85

                  • AST Federated Aggressive Growth

                  •  

                    2,134,690

                  • 0.00

                  • 3.07

                  • Federated Kaufmann Small Cap Fund

                  •  

                    1,958,600

                  • -2.79

                  • 2.82

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,170,474

                  • 0.00

                  • 1.68

                  • iShares Russell 2000 (AU)

                  •  

                    1,097,314

                  • -1.00

                  • 1.42

                  • iShares Nasdaq Biotechnology

                  •  

                    929,735

                  • 3.08

                  • 1.21

                  • Vanguard Extended Market Index Fund

                  •  

                    657,580

                  • 4.35

                  • 0.95

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    607,944

                  • 0.00

                  • 0.87

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Global Inv Mgmt Corp

                  •  

                    13,508,290

                  • +532.80%

                  • 19.42

                  • Broadfin Capital, LLC

                  •  

                    8,951,169

                  • +145.13%

                  • 12.87

                  • Baker Bros Advisors LLC

                  •  

                    4,449,797

                  • 0.00%

                  • 6.40

                  • Fidelity Management and Research Company

                  •  

                    4,076,046

                  • -7.49%

                  • 5.86

                  • BlackRock Fund Advisors

                  •  

                    2,594,840

                  • -6.03%

                  • 3.73

                  • Tudor Investment Corp Et AL

                  •  

                    2,342,388

                  • 0.00%

                  • 3.37

                  • Vanguard Group, Inc.

                  •  

                    1,921,462

                  • +3.54%

                  • 2.76

                  • Highland Capital Management L.P.

                  •  

                    1,591,528

                  • +15.02%

                  • 2.29

                  • Wellington Management Company, LLP

                  •  

                    1,569,104

                  • +1.52%

                  • 2.26

                  • State Street Corp

                  •  

                    995,936

                  • +0.15%

                  • 1.43

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidat...morees are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase ...more2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.lessless

                  Key People

                  Mr. Mark R. Baker

                  CEO/Director/President

                  Dr. Paul J. Maddon

                  Director/Founder/Vice Chairman of the Board

                  Mr. Peter J. Crowley

                  Chairman of the Board/Director

                  Mr. Angelo W. Lovallo, Jr

                  CFO/Chief Accounting Officer/Treasurer/Vice President, Divisional

                  Dr. Robert J. Israel,M.D.

                  Executive VP, Divisional

                  • Progenics Pharmaceuticals Inc

                  • 777 Old Saw Mill River Road

                  • Tarrytown, NY 10591

                  • USA.Map

                  • Phone: +1 914 789-2800

                  • Fax: +1 914 789-2817

                  • progenics.com

                  Incorporated

                  1988

                  Employees

                  69

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: